Gupta, S. K., Kizilbash, S. H., Carlson, B. L., Mladek, A. C., Boakye-Agyeman, F., Bakken, K. K., . . . Sarkaria, J. N. (2015). Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J Natl Cancer Inst.
Style de citation ChicagoGupta, Shiv K., et al. "Delineation of MGMT Hypermethylation As a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma." J Natl Cancer Inst 2015.
Style de citation MLAGupta, Shiv K., et al. "Delineation of MGMT Hypermethylation As a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma." J Natl Cancer Inst 2015.
Attention : ces citations peuvent ne pas être correctes à 100%.